Merck acquires Terns Pharmaceuticals for $6.7 billion to expand cancer pipeline

Merck & Co. (NYSE: MRK) announced today that it will acquire clinical-stage biotech Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in a $6.7 billion all-cash deal, paying $53 per share, according to a Terns Pharmaceuticals press release. The acquisition strengthens Merck’s oncology and hematology pipeline, particularly in the treatment of chronic myeloid leukemia (CML), and marks a major U.S. healthcare M&A deal.

Merck’s strategic oncology pipeline expansion with Terns Pharmaceuticals acquisition

At the heart of this acquisition is TERN‑701, Terns’ lead investigational therapy. This oral allosteric BCR::ABL1 tyrosine kinase inhibitor targets patients with CML who have resistance or intolerance to existing therapies. Early clinical trials show promising safety and tolerability, making it a potential blockbuster in the hematology market. For Merck, acquiring TERN‑701 represents both an opportunity to diversify its oncology pipeline and a hedge against future revenue pressures, particularly with Keytruda facing patent expirations later this decade.

The deal structure is straightforward. Merck will initiate a cash tender offer followed by a short-form merger, which will make Terns a wholly-owned subsidiary. The transaction is expected to close in the second quarter of 2026, pending regulatory approvals under the Hart-Scott-Rodino Act and a majority shareholder tender. By paying a premium above Terns’ recent trading price, Merck ensures immediate value for shareholders while positioning itself to integrate Terns’ hematology drug pipeline efficiently.

Analyst and investor response to Merck–Terns biopharma deal

According to reports, the market reacted positively. Analysts highlighted the premium paid for Terns’ shares and the potential of TERN‑701 to become a high-value therapy. Analysts highlighted the strategic value for Merck’s oncology portfolio. Investors see the $53-per-share offer as a strong incentive, providing liquidity and a clear path for long-term growth.

U.S. biotech M&A trends highlighted by Merck–Terns acquisition

Industry observers say this acquisition reflects a broader trend in U.S. biotech M&A, where large pharma companies are increasingly acquiring clinical-stage biotechs to strengthen pipelines and gain access to innovative therapies. The high premium paid in the Merck–Terns deal reflects the competitive environment and growing demand for promising oncology assets. It also highlights the importance of oncology pipeline expansion and strategic acquisitions of clinical-stage biotech companies, as firms seek therapies that address unmet medical needs while preparing for revenue erosion from aging patents.

Regulatory approval and integration of TERN‑701 into Merck’s hematology pipeline

Merck will proceed with regulatory filings required for antitrust and standard approval processes. Upon closing, Terns will be integrated into Merck’s operations, and TERN‑701 will advance through clinical development and eventual commercialization plans. Analysts project that successful development could result in multi-billion-dollar peak annual sales, complementing Merck’s broader oncology portfolio and reinforcing its competitive position in hematology and targeted cancer therapies.

Conclusion: strategic Merck M&A strengthens U.S. oncology leadership

The $6.7 billion Merck–Terns deal announced today demonstrates Merck’s commitment to oncology leadership, pipeline expansion, and shareholder value. By acquiring TERN‑701, Merck gains a promising leukemia therapy, strengthens its competitive edge, and prepares for future challenges in the U.S. and global cancer markets. This acquisition is a significant event in U.S. biotech M&A and will likely influence future deal-making, valuations, and strategic partnerships across the pharmaceutical sector.

With this acquisition, Merck reinforces its position as a leader in U.S. biotech M&A, securing a strong foothold in oncology pipeline expansion and advancing its hematology drug pipeline. The integration of TERN‑701 leukemia therapy underscores Merck’s strategic focus on innovative clinical-stage biotech acquisitions to address unmet chronic myeloid leukemia treatment needs.